The Public Technology Service Platform for New Drug Research and Development of the Zhongshan Institute, Institute of Pharmaceutical Innovation, Chinese Academy of Sciences (hereinafter referred to as the Zhongshan Institute) was completed and put into trial operation at the Biomedical Demonstration Zone of Zhongshan Sino-Swiss (European) Industrial Park in Tsuihang New District on December 5. [Photo by Sui Shengwei]

About 100 million yuan has been invested in the Platform, which has a construction area of 7,000 square meters. After all the equipment is commissioned, this Platform will be able to provide high-quality public services to the industry.

This Platform is constructed and strictly managed in accordance with China and the European Union GMP certification standards. It can thus carry out metabolic analysis, pharmacodynamic evaluation and drug safety evaluation for preclinical drug research, and technical services for preparation and biological macromolecular drug research and development.

Furthermore, taking into account the needs of Zhongshan's biomedical companies, this Platform will carry out consistency evaluation services to provide all-round supporting services such as personnel training, applied research and development, incubation and cultivation, and industrial amplification for original new drugs from R&D to industrialization, in a bid to drive Zhongshan in building a biomedical science and technology industrial cluster with life science as the core.

A seminar on the transfer and transformation of achievements sponsored by the Drug Innovation Institute, Chinese Academy of Sciences and hosted by the Zhongshan Institute was organized in Zhongshan on that same day. More than 30 leaders and experts from member units of the Drug Innovation Institute attended this seminar.